Valuation: Voyageur Pharmaceuticals Ltd.

Market Cap 3.06Cr 2.16Cr 1.89Cr 1.74Cr 1.61Cr 206.11Cr 3.11Cr 21Cr 8.18Cr 101.54Cr 8.11Cr 7.94Cr 349.07Cr P/E 2024
-5.24x
P/E 2025 -7.5x
Enterprise Value 3.03Cr 2.14Cr 1.88Cr 1.73Cr 1.6Cr 204.56Cr 3.08Cr 21Cr 8.12Cr 100.77Cr 8.05Cr 7.88Cr 346.43Cr EV / Sales 2024
-
EV / Sales 2025 2,42,35,81,172x
Free-Float
93.07%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Executive Officer - 01/07/2019
Director of Finance/CFO - 17/08/2022
Chief Tech/Sci/R&D Officer - 17/09/2024
Director TitleAgeSince
Director/Board Member - 06/12/2017
Director/Board Member - 01/07/2019
Chairman - 30/04/2025
Change 5-day change 1-year change 3-year change Capi.($)
-.--%+7.14% - - 2.16Cr
-2.33%-2.09%+49.88%+170.51% 1,06000Cr
-0.82%-2.30%+63.79%+62.00% 62TCr
-0.73%-4.98%+28.91%+82.99% 44TCr
+0.33%-1.17%+31.07%+27.09% 33TCr
-0.02%-2.85%+29.15%+45.24% 28TCr
-3.89%-11.22%+22.81%+27.30% 27TCr
+0.66%-1.42%-26.59%-37.71% 22TCr
-0.06%-2.88%+23.07%+62.33% 20TCr
-3.72%-1.10%+18.41%+70.56% 16TCr
Average -1.06%-3.25%+26.72%+56.70% 39.71TCr
Weighted average by Cap. -1.31%-2.96%+36.75%+83.91%

Financials

2024 2025
Net sales - 0.01 0.01 0.01 0.01 0.01 0.79 0.01 0.08 0.03 0.39 0.03 0.03 1.33
Net income -17.07L -12.07L -10.56L -10L -9L -12Cr -17.36L -1.16Cr -45.71L -5.67Cr -45.34L -44.35L -20Cr -35.33L -24.98L -21.85L -20.16L -18.62L -24Cr -35.92L -2.41Cr -94.58L -12Cr -93.81L -91.77L -40Cr
Net Debt -1L -79.66T -69.68T -64.27T -59.36T -75.97L -1L -8L -3L -37.43L -3L -3L -1.29Cr -2L -2L -1L -1L -1L -1.56Cr -2L -15.72L -6L -76.61L -6L -6L -2.63Cr
Logo Voyageur Pharmaceuticals Ltd.
Voyageur Pharmaceuticals Ltd. is a Canada-based company engaged in the development of barium and iodine active pharmaceutical ingredients (API) and imaging contrast agents for medical radiology. It focuses on vertically integrating the barium and iodine contrast markets. In addition, Voyageur is pursuing the development of new endo fullerene drugs. Its products include SmoothX, SmoothHD, SmoothLD, VisionHD, VisionLD and V-Gas. SmoothX (2%w/v) is a contrast medium for use in computed tomography (CT) of the gastrointestinal tract. VisionHD is a high-density (98% w/w) barium powder suspension tailored for double-contrast radiographic examination of the gastrointestinal tract, esophagus, stomach and duodenum. At the core of its operations, the Company also owns a 100% interest in the Frances Creek Project, which boasts a mineral suitable for the pharmaceutical marketplace that is intended to replace the current synthetic products with quality imaging products.
Employees
-

Annual profits - Rate of surprise